Abstract
-mobilizing second messengers, NAADP and cADPR, in the cardiac hypertrophy induced by β-adrenergic stimulation by isoproterenol. Isoproterenol induced an initial Ca 2+ transients followed by sustained Ca 2+ rises. Inhibition of the cADPR pathway with 8-Br-cADPR abolished only the sustained Ca 2+ increase, whereas inhibition of the NAADP pathway with bafilomycin-A1
abolished both rapid and sustained phases of the isoproterenol-mediated signal, indicating that the Ca 2+ signal is mediated by a sequential action of NAADP and cADPR. The sequential production of NAADP and cADPR was confirmed biochemically. The isoproterenolmediated Ca 2+ increase and cADPR production, but not NAADP production, were markedly reduced in cardiomyocytes obtained from CD38 knockout mice. CD38 knockout mice were rescued from chronic isoproterenol infusion-induced myocardial hypertrophy, interstitial fibrosis, and decrease in fractional shortening and ejection fraction. Thus, our findings indicate that β-adrenergic stimulation contributes to the development of maladaptive cardiac hypertrophy via Ca 2+ signaling mediated by NAADP-synthesizing enzyme and CD38 that produce NAADP and cADPR, respectively.
Introduction
In cardiac cells, Ca 2+ has a fundamental role in the regulation of both contraction and transcription [1] [2] [3] . Cardiac hypertrophy and heart failure may arise from inappropriate remodeling of the Ca 2+ signaling components [4] . The heart is a highly plastic organ that undergoes hypertrophy in response to different types of stimuli [5, 6] . The remodeling responsible for cardiac hypertrophy is a compensatory mechanism that increases the stroke volume to meet the work demand of the body, and it is reversible, in that the heart will return to its original size if the abnormal stimuli are removed within a critical time period [7, 8] If certain pathological conditions persist, however, the cardiac hypertrophy can become decompensated, shifting to the more irreversible state of heart failure [9, 10] . It is therefore important to determine which Ca 2+ signaling processes control the development of cardiac hypertrophy. Persistent activation of the β-adrenergic and renin-angiotensin-aldosterone systems (RAS) is a hallmark of cardiac hypertrophy and subsequent heart failure, in which norepinephrine (NE) and angiotensin II (AngII) are the primary effectors that mediate the hypertrophic and fibrotic events in the heart [11] [12] [13] [14] . Therefore, most current therapies for heart failure are focused on antagonizing the adrenergic system and RAS [15] . NE and AngII bind to their respective G-protein-coupled receptors (GPCRs) and induce several intracellular signaling pathways involved in the hypertrophic remodeling of the heart. Studies in animal and human models show that abnormalities in Ca 2+ handling is an important cause of hypertrophy and failing of the myocardium that occur in response to a long term and sustained stimulation by NE or AngII [16] . Thus, a clear understanding of the mechanisms by which NE and AngII modulate Ca 2+ signaling in cardiomyocytes is important.
Mounting evidence indicates that cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) play an essential role in Ca 2+ mobilization from Ca 2+ stores such as during excitation-contraction coupling in the heart [17] [18] [19] [20] . ADP-ribosyl cyclases (ARCs) produce two NAD(P)-derived Ca 2+ mobilizing second messengers, cADPR and NAADP [18, 21] . One ARC named CD38 has been cloned and characterized, and is expressed ubiquitously [22] . However, there are as-yet-unidentified non-CD38 ARCs and NAADP-synthesizing enzymes in mammalian tissues, including the heart [23] [24] [25] [26] . Our recent study showed that the AngII-induced increase in [Ca 2+ ] i was not significantly different in cardiomyocytes obtained from CD38 knockout (KO) and wild-type (WT) mice, and was completely inhibited by 8-bromo-cADP-ribose (8-Br-cADPR), indicating that cADPR was generated by an ARC other than CD38 [23] . We have recently demonstrated that bisphenyl compounds, 4,4'-and 2,2'-dihydroxyazobenzene (4DAB or 2DAB), inhibit the activity of non-CD38 ARCs in murine mesangial cells and cardiomyocytes, respectively [27, 28] . Moreover, these compounds inhibited AngII-mediated cADPR formation and hypertrophic responses in the kidney and heart [27, 29] . Taken together, these data indicate that aberrant expression or abnormal activity of ARCs results in pathological cardiac hypertrophy due to altered Ca 2+ signaling and suggest that components of Ca 2+ signaling systems could be potential targets for pharmaceutical intervention. The aim of the present study was to identify the roles of CD38 and non-CD38 ARCs and the signals generated by these enzymes in Ca 2+ signaling during cardiac hypertrophic remodeling. We focused on Ca 2+ signaling in a well-established β-adrenergic receptor (β-AR) signaling pathway that produces cardiac hypertrophy. 
Materials and Methods Animals

Osmotic Mini pump Infusion of Isoproterenol
To generate β-adrenergic-induced cardiac hypertrophy, isoproterenol (ISO, Sigma-Aldrich) (10 mg/kg/day) or vehicle (ddH 2 O) was administrated to 8-week-old male CD38 KO and WT mice via osmotic mini-pumps (Alzet) implanted subcutaneously. Hearts were isolated and analyzed for cardiac hypertrophy following 7 days of ISO infusion.
Echocardiography
Left ventricular (LV) dimensions were assessed by echocardiography using a GE Vivid 4 ultrasound machine (GE Medical Systems, Waukesha, Wisconsin, USA) equipped with a 13-MHz phase array linear transducer. M-mode images were used for measurement of wall thickness, chamber dimension, fractional shortening (FS), and ejection fraction (EF) in anesthetized rats. EF provides a global assessment of left ventricular systolic performance and can be estimated using the equation described previously [27] .
Histological Analysis
Hearts were fixed with 4% paraformaldehyde and embedded in paraffin, and 6-μm thick sections were stained with hematoxylin and eosin or Masson's trichrome [27] . Images were acquired using a Nikon ECLIPSE E600 microscope (Nikon Japann) with a 40x objective lens (Plan Apo40/0.95, Nikon, Japan) and a digital camera (Nikon DXm1200F, Nikon, Japan) and software (Nikon ACT-12.62, Nikon, Japan). The area of one image was 0.086 mm 2 . The number of cardiomyocytes per high-powered field (× 400) was counted by two pathologists. To evaluate the fibrosis of the heart, four images were taken per group at 400x magnification with Masson's Trichrome staining (MTS) slides. The images were analyzed with image analyzing software (analySIS, Soft Imaging Systems, Germany), and the MTS-positive area was calculated as following: MTS-positive area = (MTS-stained blue-colored area/total area) x 100 (%).
Preparation of Cardiomyocytes
Ventricular cardiomyocytes were isolated from rats (200-220 g) and C57BL/6 CD38 KO and WT mice (25-30 g ) using a modification of the method described previously [23] . Briefly, animals were sacrificed by cervical dislocation. Isolated cardiomyocytes were seeded on plates previously coated with laminin (10 μg/ml; Sigma) for 1 hour. After incubation for 20 minutes at 37°C in a humidified incubator with 5% CO 2 /95% air atmosphere, the medium was changed to remove round and unattached cells. This technique routinely yields > 90% cardiomyocytes that retain a rod-shaped morphology. Experiments were performed 12-16 hours after isolation. Before treatment with blockers or ISO, cardiomyocytes were incubated in a buffer containing 20 mM HEPES, 137 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO 4 , 15 mM glucose, and 1 mM Ca 2+ for 20 minutes.
Pretreatment of Cardiomyocytes
Cardiomyocytes were treated with the indicated concentrations of blockers and incubated at 37°C for 30 minutes prior to ISO-treatment as follows: H89 (10 μM), Rp-cAMP (100 μM), thapsigargin (10 μM), 8-Br-cADPR (100 μM), DAB (1 μM), xestospongin C (2 μM), nifedipine (10 μM), SKF 96365 (10 μM) and bafilomycin A1 (1 μM). ] i were determined at 488 nm excitation/530 nm emission by an air-cooled argon laser system [23] . The emitted fluorescence was collected using a photomultiplier. One image was scanned every 3 s using a confocal microscope (Nikon). [Ca 2+ ] i calculation was performed using the equation [Ca
is 450 nM for fluo3 and F is the observed fluorescence levels [30] . Each tracing was calibrated for the maximal intensity (F max ) by the addition of 8 μM ionomycin and for the minimal intensity (F min ) by the addition of 50 mM EGTA at the end of each measurement.
Measurement of Intracellular cADPR and NAADP Concentrations
A cyclic enzymatic assay was used to measure cADPR and NAADP levels as described previously [23] . Fluorescence was measured at excitation/emission wavelengths of 544/590 nm using a fluorescence plate reader (Molecular Devices Corp., Spectra-Max GEMINI).
Immunoblotting
Protein extraction and immunoblotting of cardiomyocytes were performed as previously described [23, 27] . Signals were detected using the enhanced chemiluminescence system (BioRad, Munich, Germany). For quantitative measurements, blots were scanned, and band density was normalized to the density of a control protein band for each sample. Protein concentrations were determined using the Bio-Rad protein assay kit, and known concentrations of BSA were used as the standard.
Lentiviral Transduction
Isolated rat cardiomyocytes were plated in 6-well plates 8 hours prior to viral infection. Cardiomyocytes were transduced with lentiviral particles encoding CD38 from Santa Cruz Biotechnology (Santa Cruz, CA) at a multiplicity of infection (MOI) of 1-3. Lentiviral transduction was performed essentially according to the manufacturer's protocol. Briefly, the media was replaced with media 199 (Invitrogen, Grand Island, NY) containing 5 μg/ml polybrene. Cells were infected overnight with lentiviral particles containing CD38 or control shRNA. The next day, the media was changed and cells were incubated for 12 hours before analysis. Knockdown efficiency was confirmed by immunoblotting.
Knockdown of Stim1 by small interference RNA (siRNA)
Stim1 siRNA was purchased from Invitrogen (Cat. 64647, 151019). Cardiac cells were cultured in an antibiotic-free growth media supplemented with fetal bovine serum. After 6 hours, cardiac cells were transfected with 60 pmol of siRNA oligonucleotides specific to Stim1 using transfection reagent (Quagen. cat.301305) without antibiotics according to the instructions of the manufacturer. After 48 hours of transfection, cells were prepared for examination.
Statistical Analysis
Data represent means ± standard error of the mean (SEM) of at least three separate experiments. Differences were compared by analysis of variance (ANOVA) followed by Student's ttests. Two-group analysis was performed using Student's t-test (paired or unpaired, as appropriate). Statistical analysis for the MTS-positive area was performed by one-way ANOVA followed by a Tukey HSD post-hoc test. A value of P < 0.05 was considered significant. -free medium and then Ca 2+ added to the bath perfusion solution to assess the presence of SOCE, as described earlier [35] . Depletion of Ca 2+ stores by deazacADPR induced Ca 2+ entry in the presence of extracellular Ca 2+ (Fig 1F) , indicating that the sustained Ca 2+ signal is mediated by SOCE following Ca 2+ mobilization by cADPR. In keeping (Fig 1G) .
Results
Isoproterenol
The results shown in Fig 1 suggest that NAADP and cADPR are sequentially generated in ISO-treated cardiomyocytes. To test this further, we determined the kinetics of production of these Ca 2+ -mobilizing messengers in response to ISO. Treatment of cardiomyocytes with ISO increased NAADP and cADPR production in a time-dependent manner, with peaks at about 15 and 30 s, respectively (Fig 2A) . As predicted, ISO-mediated production of NAADP and cADPR was abolished in cells treated with H89 or Rp-cAMP (Fig 2B and 2C) . These results indicate that the rise in cAMP level ([cAMP]) is a prerequisite for the ISO-induced production of the Ca 2+ -mobilizing second messengers, and support earlier findings that cAMP is specifically responsible for NAADP generation [24, 36, 37] .
Bafilomycin blocked the ISO-induced formation of NAADP and cADPR to the control basal level (Fig 2B and 2C) indicating that NAADP is formed in acidic organelles and that its formation precedes the cADPR formation. This is consistent with our biochemical data also showing that formation of NAADP precedes that of cADPR (Fig 2A) . Thus, NAADP appears to be the trigger for the formation of cADPR. In agreement with the lack of effect of XesC on the ISO-induced Ca 2+ signal (Fig 1B and 1C) , XesC failed to inhibit ISO-induced cADPR and NAADP production (Fig 2B and 2C) . Thus, ISO stimulates the production of NAADP that in turn leads to elevation of cADPR, and these effects are independent of IP 3 -mediated Ca 2+ release. 3A) . In keeping with this finding, ISO-induced cADPR production was abrogated in cardiomyocytes from CD38 KO mice (Fig 3B) . By contrast, ISO-induced NAADP production was not reduced in cardiomyocytes from CD38 KO mice (Fig 3C) . These results indicate that CD38 is responsible for cADPR production, but not NAADP production, in ISO-treated cardiomyocytes. To confirm the above finding that ISO-induced sustained increase in [Ca 2+ ] i requires CD38 (Fig 3) , short hairpin RNA (shRNA) directed against CD38 was used to down-regulate its gene expression. Treatment of cardiomyocytes with lentiviral transduction particles containing CD38 shRNAs overnight reduced the CD38 protein level by~90%, as assessed by immunoblot analyses (S1A 
CD38 Mediates ISO-induced cADPR but not NAADP Production in Cardiomyocytes
Loss of CD38 Markedly Reduces the Hypertrophic Response and Preserves Cardiac Function Following Chronic ISO Infusion
The requirement of CD38 for ISO-induced sustained increase in [Ca 2+ ] i suggests that CD38 may also be necessary for ISO-induced hypertrophy. To test this directly, WT and CD38 KO mice were subjected to chronic infusion of ISO (Fig 4) . Infusion of ISO (10 mg/kg per day) for 1 week induced advanced hypertrophy in WT mice, but not in CD38 KO mice (Fig 4A and  4B) . After ISO infusion, the cell enlargement in WT mice was significantly greater than that in CD38 KO mice (Fig 4B) . The cross-sectional area of cardiomyocytes increased by 113% in CD38 WT mice, but by only 30% in CD38 KO mice. The heart weight/body weight ratios (HW/BW) also increased significantly in WT mice, but not in CD38 KO mice after ISO infusion. (Fig 4B) . Histological analysis revealed a significant increase in cardiac fibrosis in ISOinfused WT mice, but not in CD38 KO mice (Fig 4C and 4D) . Consistent with these findings, the levels of hypertrophic and fibrosis markers (fibronectin and TGF-β1) were elevated in CD38 WT, but not CD38 KO, 7 days following ISO-treatment (S3 Fig). Consistent with the hypertrophic and fibrotic responses to ISO in WT mice, chronic infusion of WT mice with ISO also led to a significant reduction of fractional shortening and ejection fraction, indicating an impairment of cardiac function (Fig 4E and 4F, Table 1 ). By contrast, cardiac function was preserved in CD38 KO mice following ISO infusion (Fig 4E and  4F , Table 1 ). ARC activity and cADPR levels were also not increased in ISO-infused CD38 KO mice, while NAADP levels did increase in CD38 KO mice in response to ISO (Fig 4G-4I) . Collectively, these results indicate that deletion of CD38 reduces the hypertrophic response to ISO infusion and preserves cardiac function, and that cADPR-mediated Ca 2+ signaling plays a critical role in ISO-induced cardiac hypertrophy and fibrosis. 
Discussion
In the present study we demonstrate that stimulation of β-AR in cardiomyocytes by ISO induces a sustained [Ca 2+ ] i increase via the production of NAADP and cADPR by an NAADP-synthesizing enzyme and CD38, respectively. In WT mice, ISO induced myocardial hypertrophy, interstitial fibrosis, and cardiac dysfunction, whereas in CD38 KO mice, ISO failed to induce hypertrophy and cardiac function was preserved. Moreover, inhibition of CD38 activity ameliorated ISOinduced cardiac hypertrophy and fibrosis in vivo. Thus, an NAADP synthesizing enzyme and CD38 play a crucial role in ISO-induced remodeling of cardiac morphology and function.
ISO-induced Ca
2+ signaling via NAADP and cADPR
Sustained β-adrenergic stimulation has been implicated in the development of cardiac hypertrophy and heart failure. Indeed, altered signaling via the G-protein-coupled β-ARs has been implicated in heart failure in animal models and humans [6] [7] [8] 10] . ISO binds both β1 and β2 receptors, but only β1-receptor-mediated signaling has been shown to cause cardiac hypertrophy [38] . ] i and production of NAADP and cADPR indicates that, upon stimulation of β-AR, CD38 and an NAADP-synthesizing enzyme are activated by a cAMP-dependent mechanism. At present, how cAMP causes activation of these enzymes is not clear. The observation that NAADP-AM, a cell-permeable NAADP analog, induces a sustained Ca 2+ signal only in the presence of extracellular Ca 2+ suggests that ISO-induced Ca 2+ signal is initiated by Ca 2+ influx which is dependent on PKA (Fig   1) . Therefore, cAMP may be the trigger that initiates the Ca 2+ influx, leading to the activation of an NAADP synthesizing enzyme. NAADP-induced Ca 2+ release from acidic stores would then activate CD38 to generate cADPR and cause SR Ca 2+ depletion and induction of SOCE, resulting in a sustained Ca 2+ signal (Fig 5) . Concerning the effect of CD38 on the expression of β-AR, β1-AR and β2-AR levels of CD38 WT and CD38 KO were similar (S2 Fig). The level of β2-AR, but not β1-AR, was decreased by ISO treatment in both groups (S2 Fig), consistent with the data of Dangel et al [42] who showed that ISO-treated cardiac cells displayed changes of β1:β2 ratio, due to the decreased β2 receptor in ISO treated cells. Thus, β-AR expression was not affected by CD38.
Role of a non-CD38, NAADP-synthesizing enzyme in ISO-induced Ca 2+ signaling CD38 is an ARC that is capable of producing both cADPR and NAADP. Our data obtained with CD38 KO mice and CD38 knockdown (Figs 3D, 4I and S1D) show that ISO-induced NAADP production is not dependent on CD38. Therefore, multiple enzymes probably exist for the generation of cADPR/NAADP in the heart, and cardiomyocytes very likely express an NAADP-synthesizing enzyme that is regulated in a cAMP-dependent manner. This is supported by the observation that extracts prepared from the tissues of CD38 KO mice, including the heart, were incapable of synthesizing NAADP by the base-exchange reaction in vitro, and that the in vivo cellular NAADP content was not reduced by the absence of CD38 [26] . Therefore, neither CD38 nor the base-exchange reaction may be necessary for the in vivo generation of NAADP. Consistent with this finding, our data ( Figs 3D, 4I and S1D) clearly demonstrate that CD38 is not responsible for NAADP generation in ISO-stimulated cardiomyocytes. It will be interesting to determine how each ARC enzyme is linked to a specific downstream signaling pathway in physiological and pathological states.
Role of ARC in ISO-induced cardiac dysfunction
An important finding of this study is that CD38 KO mice are protected from pathological hypertrophy induced by chronic ISO infusion. ISO infusion increased ARC activity and cADPR production in WT mice, resulting in ventricular fibrosis and hypertrophy and impaired cardiac function. ISO did not produce such detrimental cardiac effects in CD38 KO mice. In line with these findings, ISO-mediated [Ca 2+ ] i increase and cADPR production were abolished in cardiomyocytes obtained from CD38 KO mice or in cardiomyocytes in which CD38 was knocked down with shRNA. Thus, CD38 is responsible for eliciting the ISO-induced [Ca 2+ ] i response and the synthesis of cADPR. We previously demonstrated that inhibition of a non-CD38 ARC by a small molecule inhibitor called 2DAB blocked Ang II-induced sustained [Ca 2+ ] i increase and production of cADPR in adult rat cardiomyocytes. Moreover, 2DAB attenuated Ang II-induced hypertrophic responses as indicated by the decrease in NFAT nuclear translocation, TGF-1β protein expression, and [ 3 H]-leucine incorporation [27] . Consistent with these findings, 2DAB was capable of preventing the development of cardiac hypertrophy in rat renovascular hypertension model, a renin angiotensin-dependent two-kidney one-clip model of hypertension [27] . Taken together, our findings suggest that CD38 and/or non-CD38 ARCs in the myocardium could be targets for the treatment of cardiac hypertrophy. Specific intervention should be possible if the exact underlying cellular mechanisms of pathogenesis of the cardiac hypertrophy are determined.
Comparison with AngII-induced Ca 2+ signaling
In contrast to the dependency of ISO-mediated Ca 2+ signaling on CD38 and NAADP-synthesizing enzyme, AngII was found to induce cardiac hypertrophic remodeling and increase cADPR production in a CD38-independent manner [23] . The difference in the modes of Ca 2+ signaling elicited by ISO and AngII can be attributed to activation of different GPCRs. Several lines of evidence indicate that stimulation of AngII receptor activates ARC to produce cADPR in cardiomyocytes [39] . Our recent study show that AngII activates an ARC other than CD38 to induce a sustained rise in [Ca 2+ ] i and cardiac hypertrophy [27] . Inhibition of ARC with 2DAB significantly attenuated AngII-induced cardiac hypertrophic responses in an AngIIdependent model of hypertension [27] . Furthermore, 2DAB significantly inhibited AngIImediated cADPR formation and hypertrophic responses in vitro. Therefore, a non-CD38 ARC is likely to be coupled to AngII receptor. Thus, β-AR and AngII receptors recruit different effectors (CD38 or non-CD38 ARC) to produce a common product, cADPR, to produce pathological hypertrophy.
